Clinical trial
Impact of an Immuno-radiomic Signature on Intracranial Treatment Efficacy in Non-small Cell Lung Cancer With Brain Metastases at Diagnosis
NCT07904013 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Impact of an Immuno-radiomic Signature on Intracranial Treatment Efficacy in Non-small Cell Lung Cancer With Brain Metastases at Diagnosis
- Lead sponsor
- University Hospital, Bordeaux
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- December 31, 2028
- Enrollment
- 38 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
brain neoplasms, carcinoma, neoplasm metastasis, non-small-cell lung
Arms
As registered; 1 arm.
-
Patients with brain metastases from NSCLC
Patients aged 18 years or older with advanced or metastatic non-small cell lung cancer, at least one resected brain metastasis at diagnosis, and an indication for first-line immunotherapy plus chemotherapy
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Correlation between MRI-based radiomic signature and transcriptomic signature of brain metastases
Correlation between quantitative radiomic features extracted from brain MRI and transcriptomic profiles obtained from bulk RNA sequencing of resected brain metastasis tissue
Lead sponsor's other trials
University Hospital, Bordeaux, most recent start first.
+801 more trials
Similar trials
Same condition (Brain Neoplasms) and phase, most recent start first.
+426 more trials See the condition page